Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2018, Article ID 8473161, 12 pages
https://doi.org/10.1155/2018/8473161
Research Article

Metabolomics of Hydrazine-Induced Hepatotoxicity in Rats for Discovering Potential Biomarkers

1Pharmacy Department of Beijing Chao-Yang Hospital Affiliated with Beijing Capital Medical University, Beijing, China
2Pharmacy Department of the Second Artillery General Hospital of Chinese People’s Liberation Army, Beijing, China

Correspondence should be addressed to Lihong Liu; moc.621@hllgnoh

Received 15 August 2017; Accepted 20 November 2017; Published 10 April 2018

Academic Editor: Donald H. Chace

Copyright © 2018 Zhuoling An et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. S. Goldberg, K. A. Forde, D. M. Carbonari et al., “Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system,” Gastroenterology, vol. 148, no. 7, pp. 1353–1361.e3, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Chalasani, R. J. Fontana, H. L. Bonkovsky et al., “Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States,” Gastroenterology, vol. 135, no. 6, pp. 1924–1934.e4, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Idilman, M. Bektas, K. Cinar et al., “The characteristics and clinical outcome of drug-induced liver injury: a single-center experience,” Journal of Clinical Gastroenterology, vol. 44, no. 6, pp. e128–e132, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Robles, E. Toscano, J. Cotta, M. Lucena, and R. J. Andrade, “Antibiotic-induced liver toxicity: mechanisms, clinical features and causality assessment,” Current Drug Safety, vol. 5, no. 3, pp. 212–222, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. B. E. Senousy, S. I. Belal, and P. V. Draganov, “Hepatotoxic effects of therapies for tuberculosis,” Nature Reviews Gastroenterology & Hepatology, vol. 7, no. 10, pp. 543–556, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. J. A. Agúndez, M. I. Lucena, C. Martínez et al., “Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity,” Expert Opinion on Drug Metabolism & Toxicology, vol. 7, no. 7, pp. 817–828, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. E. S. Björnsson, “Drug-induced liver injury due to antibiotics,” Scandinavian Journal of Gastroenterology, vol. 52, no. 6-7, pp. 617–623, 2017. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Chen, H. Bisgin, L. Tong et al., “Toward predictive models for drug-induced liver injury in humans: are we there yet?” Biomarkers in Medicine, vol. 8, no. 2, pp. 201–213, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. A. W. Nicholls, E. Holmes, J. C. Lindon et al., “Metabonomic investigations into hydrazine toxicity in the rat,” Chemical Research in Toxicology, vol. 14, no. 8, pp. 975–987, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Garrod, M. E. Bollard, A. W. Nicholls et al., “Integrated metabonomic analysis of the multiorgan effects of hydrazine toxicity in the rat,” Chemical Research in Toxicology, vol. 18, no. 2, pp. 115–122, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. M. E. Bollard, H. C. Keun, O. Beckonert et al., “Comparative metabonomics of differential hydrazine toxicity in the rat and mouse,” Toxicology and Applied Pharmacology, vol. 204, no. 2, pp. 135–151, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. D. J. Crockford, E. Holmes, J. C. Lindon et al., “Statistical heterospectroscopy, an approach to the integrated analysis of NMR and UPLC-MS data sets: application in metabonomic toxicology studies,” Analytical Chemistry, vol. 78, no. 2, pp. 363–371, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. T. G. Klenø, B. Kiehr, D. Baunsgaard, and U. G. Sidelmann, “Combination of ‘omics’ data to investigate the mechanism(s) of hydrazine-induced hepatotoxicity in rats and to identify potential biomarkers,” Biomarkers, vol. 9, no. 2, pp. 116–138, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Bando, T. Kunimatsu, J. Sakai et al., “GC-MS-based metabolomics reveals mechanism of action for hydrazine induced hepatotoxicity in rats,” Journal of Applied Toxicology, vol. 31, no. 6, pp. 524–535, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Yu, Y. Zhu, Q. Cong, and C. Wu, “Metabonomics research progress on liver diseases,” Canadian Journal of Gastroenterology and Hepatology, vol. 2017, Article ID 8467192, 10 pages, 2017. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Kakisaka, Y. Yoshida, Y. Suzuki et al., “Serum markers for mitochondrial dysfunction and cell death are possible predictive indicators for drug-induced liver injury by direct acting antivirals,” Hepatology Research, vol. 48, no. 1, pp. 78–86, 2017. View at Publisher · View at Google Scholar · View at Scopus
  17. J. K. Nicholson and I. D. Wilson, “Opinion: understanding ‘global’ systems biology: metabonomics and the continuum of metabolism,” Nature Reviews Drug Discovery, vol. 2, no. 8, pp. 668–676, 2003. View at Publisher · View at Google Scholar
  18. A. Sreekumar, L. M. Poisson, T. M. Rajendiran et al., “Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression,” Nature, vol. 457, no. 7231, pp. 910–914, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Y. Chen, Y. M. Chen, H. J. Chien et al., “Metabolic disturbances in adult-onset still’s disease evaluated using liquid chromatography/mass spectrometry-based metabolomic analysis,” PLoS One, vol. 11, no. 12, article e0168147, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. M. S. Ahmad, M. Alsaleh, T. Kimhofer et al., “Metabolic phenotype of obesity in a Saudi population,” Journal of Proteome Research, vol. 16, no. 2, pp. 635–644, 2017. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Wang, S. Liu, W. Yang et al., “Plasma amino acid profile in patients with aortic dissection,” Scientific Reports, vol. 7, article 40146, 2017. View at Publisher · View at Google Scholar · View at Scopus
  22. Z. An, Y. Chen, R. Zhang et al., “Integrated ionization approach for RRLC-MS/MS-based metabonomics: finding potential biomarkers for lung cancer,” Journal of Proteome Research, vol. 9, no. 8, pp. 4071–4081, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. A. H. Emwas, C. Luchinat, P. Turano et al., “Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review,” Metabolomics, vol. 11, no. 4, pp. 872–894, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Wuolikainen, P. Jonsson, M. Ahnlund et al., “Multi-platform mass spectrometry analysis of the CSF and plasma metabolomes of rigorously matched amyotrophic lateral sclerosis, Parkinson’s disease and control subjects,” Molecular BioSystems, vol. 12, no. 4, pp. 1287–1298, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Vignoli, D. M. Rodio, A. Bellizzi et al., “NMR-based metabolomic approach to study urine samples of chronic inflammatory rheumatic disease patients,” Analytical and Bioanalytical Chemistry, vol. 409, no. 5, pp. 1405–1413, 2017. View at Publisher · View at Google Scholar · View at Scopus
  26. I. D. Wilson, R. Plumb, J. Granger, H. Major, R. Williams, and E. M. Lenz, “HPLC-MS-based methods for the study of metabonomics,” Journal of Chromatography B, vol. 817, no. 1, pp. 67–76, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. H. G. Gika, G. A. Theodoridis, J. E. Wingate, and I. D. Wilson, “Within-day reproducibility of an HPLC-MS-based method for metabonomic analysis: application to human urine,” Journal of Proteome Research, vol. 6, no. 8, pp. 3291–3303, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Scalbert, L. Brennan, O. Fiehn et al., “Mass-spectrometry-based metabolomics: limitations and recommendations for future progress with particular focus on nutrition research,” Metabolomics, vol. 5, no. 4, pp. 435–458, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. M. S. Monteiro, M. Carvalho, M. L. Bastos, and P. Guedes de Pinho, “Metabolomics analysis for biomarker discovery: advances and challenges,” Current Medicinal Chemistry, vol. 20, no. 2, pp. 257–271, 2013. View at Publisher · View at Google Scholar
  30. M. Katajamaa and M. Oresic, “Processing methods for differential analysis of LC/MS profile data,” BMC Bioinformatics, vol. 6, no. 1, p. 179, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Chen, J. Xu, R. Zhang et al., “Assessment of data pre-processing methods for LC-MS/MS-based metabolomics of uterine cervix cancer,” The Analyst, vol. 138, no. 9, pp. 2669–2677, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Eriksson, E. Johansson, N. Kettaneh-Wold, J. Trygg, C. Wikström, and S. Wold, Multivariate and Megavariate Data Analysis Part I: Basic Principles and Applications, Umetrics Academy, Sweden, 2001.
  33. Y. Chen, R. Zhang, Y. Song et al., “RRLC-MS/MS-based metabonomics combined with in-depth analysis of metabolic correlation network: finding potential biomarkers for breast cancer,” The Analyst, vol. 134, no. 10, pp. 2003–2011, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. J. A. Swets, “Measuring the accuracy of diagnostic systems,” Science, vol. 240, no. 4857, pp. 1285–1293, 1988. View at Publisher · View at Google Scholar
  35. E. S. Lightcap and R. B. Silverman, “Slow-binding inhibition of γ-aminobutyric acid aminotransferase by hydrazine analogues,” Journal of Medicinal Chemistry, vol. 39, no. 3, pp. 686–694, 1996. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Wiklund, E. Johansson, L. Sjöström et al., “Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically interesting compounds using OPLS class models,” Analytical Chemistry, vol. 80, no. 1, pp. 115–122, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Eriksson, E. Johansson, N. Kettaneh-Wold, J. Trygg, C. Wikström, and S. Wold, Multivariate and Megavariate Data Analysis Part II: Advanced Applications and Method Extensions, Umetrics, Sweden, 2006.
  38. D. D. Wei, J. S. Wang, P. R. Wang, M. H. Li, M. H. Yang, and L. Y. Kong, “Toxic effects of chronic low-dose exposure of thioacetamide on rats based on NMR metabolic profiling,” Journal of Pharmaceutical and Biomedical Analysis, vol. 98, pp. 334–338, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Rios-Avila, H. F. Nijhout, M. C. Reed, H. S. Sitren, and J. F. Gregory 3rd, “A mathematical model of tryptophan metabolism via the kynurenine pathway provides insights into the effects of vitamin B-6 deficiency, tryptophan loading, and induction of tryptophan 2,3-dioxygenase on tryptophan metabolites,” The Journal of Nutrition, vol. 143, no. 9, pp. 1509–1519, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. X. Sun, W. Xu, Y. Zeng et al., “Metabonomics evaluation of urine from rats administered with phorate under long-term and low-level exposure by ultra-performance liquid chromatography-mass spectrometry,” Journal of Applied Toxicology, vol. 34, no. 2, pp. 176–183, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Hartmann, E. Freiberg, and W. Ruge, “Indolepatterns in the urine of liver patients,” Klinische Wochenschrift, vol. 40, no. 14, pp. 721–729, 1962. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Li, Y. Ma, X. B. Geng et al., “Drug-induced acute liver injury within 12 hours after fluvastatin therapy,” American Journal of Therapeutics, vol. 23, no. 1, pp. e318–e320, 2016. View at Publisher · View at Google Scholar · View at Scopus
  43. H. Kawasaki, T. Hori, M. Nakajima, and K. Takeshita, “Plasma levels of pipecolic acid in patients with chronic liver disease,” Hepatology, vol. 8, no. 2, pp. 286–289, 1988. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Geenen, C. Guallar-Hoyas, F. Michopoulos et al., “HPLC-MS/MS methods for the quantitative analysis of 5-oxoproline (pyroglutamate) in rat plasma and hepatic cell line culture medium,” Journal of Pharmaceutical and Biomedical Analysis, vol. 56, no. 3, pp. 655–663, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. E. H. Ali, B. McJunkin, S. Jubelirer, and W. Hood, “Niacin induced coagulopathy as a manifestation of occult liver injury,” The West Virginia Medical Journal, vol. 109, no. 1, pp. 12–14, 2013. View at Google Scholar
  46. J. Sun, L. K. Schnackenberg, R. D. Holland et al., “Metabonomics evaluation of urine from rats given acute and chronic doses of acetaminophen using NMR and UPLC/MS,” Journal of Chromatography B, vol. 871, no. 2, pp. 328–340, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. C. H. Halsted, “B-vitamin dependent methionine metabolism and alcoholic liver disease,” Clinical Chemistry and Laboratory Medicine, vol. 51, no. 3, pp. 457–465, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. L. Du, S. Li, L. Qi et al., “Metabonomic analysis of the joint toxic action of long-term low-level exposure to a mixture of four organophosphate pesticides in rat plasma,” Molecular BioSystems, vol. 10, no. 5, pp. 1153–1161, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Kępka, S. D. Szajda, N. Waszkiewicz et al., “Carnitine: function, metabolism and value in hepatic failure during chronic alcohol intoxication,” Postȩpy Higieny i Medycyny Doświadczalnej, vol. 65, pp. 645–653, 2011. View at Publisher · View at Google Scholar
  50. H. H. Mansour, “Protective role of carnitine ester against radiation-induced oxidative stress in rats,” Pharmacological Research, vol. 54, no. 3, pp. 165–171, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. H. Sun, A. H. Zhang, D. X. Zou, W. J. Sun, W. XH, and X. J. Wang, “Metabolomics coupled with pattern recognition and pathway analysis on potential biomarkers in liver injury and hepatoprotective effects of yinchenhao,” Applied Biochemistry and Biotechnology, vol. 173, no. 4, pp. 857–869, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. T. Ogiso, T. Kobayashi, K. Kuhara, and Y. Kato, “Effect of “drugs for liver disease” on hepatotoxic action of carbon tetrachloride II. Effect of protoporphyrin and phosphorylcholine on microsomal drug-metabolizing enzyme activities and the components in injuried liver,” The Japanese Journal of Pharmacology, vol. 25, no. 4, pp. 411–421, 1975. View at Publisher · View at Google Scholar · View at Scopus